PLCB3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17860410	0.75	4/20
SCHEMBL17860364	0.67	4/20
SCHEMBL17860327	0.66	4/20
SCHEMBL17860347	0.66	4/20
SCHEMBL17860353	0.66	4/20
SCHEMBL17860436	0.66	4/20
SCHEMBL17860399	0.65	4/20
SCHEMBL17860409	0.65	4/20
SCHEMBL17860393	0.64	4/20
SCHEMBL17860363	0.64	4/20
SCHEMBL17860328	0.64	4/20
SCHEMBL17860371	0.63	4/20
SCHEMBL17860418	0.63	4/20
SCHEMBL17860435	0.63	4/20
SCHEMBL17860453	0.63	4/20
SCHEMBL17860297	0.63	4/20
SCHEMBL17860314	0.62	4/20
SCHEMBL17860298	0.62	4/20
SCHEMBL16980367	0.62	4/20
SCHEMBL16984262	0.62	4/20

Clinical trials — most relevant to PLCB3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients	PHASE2	COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib	PHASE1	ACTIVE_NOT_RECRUITING
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Molecular Markers of Human Sperm Function	nan	WITHDRAWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Clinical Characteristics of Primary Liver Cancer	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Candida Associated Cytokines in Oral Leukoplakia	nan	COMPLETED
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer	nan	WITHDRAWN
Plaque Calcium Characterization and Ruptured Plaques	nan	UNKNOWN
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential	nan	NOT_YET_RECRUITING
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
Liver Cancer Prognosis Investigation Study	nan	NOT_YET_RECRUITING
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations	nan	WITHDRAWN
The Dragon PLC Trial (DRAGON-PLC)	nan	RECRUITING
Study of Proteus Syndrome and Related Congenital Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PLCB3 binder may also engage these)

Protein	Name	Similarity
P51432	—	1.000	P51432 →
Q99JE6	—	1.000	Q99JE6 →
Q00722	—	0.991	Q00722 →
Q9UPR0	—	0.989	Q9UPR0 →
O89040	—	0.989	O89040 →
A3KGF7	—	0.987	A3KGF7 →
PLCB1	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1	0.987	landscape →
A2AP18	—	0.987	A2AP18 →
Q8K394	—	0.986	Q8K394 →
Q15111	—	0.985	Q15111 →
Q8R3B1	—	0.985	Q8R3B1 →
Q62688	—	0.985	Q62688 →
P70218	—	0.985	P70218 →
P10687	—	0.983	P10687 →
G5EBH0	—	0.983	G5EBH0 →
Q9Z1B3	—	0.983	Q9Z1B3 →
PLCD1	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1	0.982	landscape →
P25455	—	0.982	P25455 →
Q3USB7	—	0.982	Q3USB7 →
P10894	—	0.982	P10894 →
O75038	—	0.981	O75038 →
Q66K14	—	0.981	Q66K14 →
P10895	—	0.980	P10895 →
Q4KWH5	—	0.980	Q4KWH5 →
O88509	—	0.980	O88509 →
Q4KWH8	—	0.979	Q4KWH8 →
Q60875	—	0.979	Q60875 →
Q9Y613	—	0.979	Q9Y613 →
Q8BML1	—	0.979	Q8BML1 →
F1RA39	—	0.979	F1RA39 →